[1]
Blair A, White DW. Leukemia cell types and agricultural practices in Nebraska. Archives of environmental health. 1985 Jul-Aug:40(4):211-4
[PubMed PMID: 4051575]
[2]
Burmeister LF, Van Lier SF, Isacson P. Leukemia and farm practices in Iowa. American journal of epidemiology. 1982 May:115(5):720-8
[PubMed PMID: 7081203]
[3]
Talibov M, Auvinen A, Weiderpass E, Hansen J, Martinsen JI, Kjaerheim K, Tryggvadottir L, Pukkala E. Occupational solvent exposure and adult chronic lymphocytic leukemia: No risk in a population-based case-control study in four Nordic countries. International journal of cancer. 2017 Sep 15:141(6):1140-1147. doi: 10.1002/ijc.30814. Epub 2017 Jun 15
[PubMed PMID: 28571111]
Level 2 (mid-level) evidence
[4]
Preston DL,Kusumi S,Tomonaga M,Izumi S,Ron E,Kuramoto A,Kamada N,Dohy H,Matsuo T,Matsui T [corrected to Matsuo T], Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiation research. 1994 Feb
[PubMed PMID: 8127953]
[5]
Schubauer-Berigan MK, Daniels RD, Fleming DA, Markey AM, Couch JR, Ahrenholz SH, Burphy JS, Anderson JL, Tseng CY. Chronic lymphocytic leukaemia and radiation: findings among workers at five US nuclear facilities and a review of the recent literature. British journal of haematology. 2007 Dec:139(5):799-808
[PubMed PMID: 17922878]
[6]
Arp EW Jr, Wolf PH, Checkoway H. Lymphocytic leukemia and exposures to benzene and other solvents in the rubber industry. Journal of occupational medicine. : official publication of the Industrial Medical Association. 1983 Aug:25(8):598-602
[PubMed PMID: 6886869]
[7]
Monson RR, Fine LJ. Cancer mortality and morbidity among rubber workers. Journal of the National Cancer Institute. 1978 Oct:61(4):1047-53
[PubMed PMID: 279710]
[8]
Brown LM,Gibson R,Blair A,Burmeister LF,Schuman LM,Cantor KP,Fraumeni JF Jr, Smoking and risk of leukemia. American journal of epidemiology. 1992 Apr 1
[PubMed PMID: 1595675]
[9]
Khalade A, Jaakkola MS, Pukkala E, Jaakkola JJ. Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis. Environmental health : a global access science source. 2010 Jun 28:9():31. doi: 10.1186/1476-069X-9-31. Epub 2010 Jun 28
[PubMed PMID: 20584305]
Level 1 (high-level) evidence
[10]
Marwick C. Link found between Agent Orange and chronic lymphocytic leukaemia. BMJ (Clinical research ed.). 2003 Feb 1:326(7383):242
[PubMed PMID: 12560261]
[11]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: a cancer journal for clinicians. 2020 Jan:70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8
[PubMed PMID: 31912902]
[12]
Hernández JA, Land KJ, McKenna RW. Leukemias, myeloma, and other lymphoreticular neoplasms. Cancer. 1995 Jan 1:75(1 Suppl):381-94
[PubMed PMID: 8001009]
[13]
Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. British journal of cancer. 2011 Nov 22:105(11):1684-92. doi: 10.1038/bjc.2011.450. Epub 2011 Nov 1
[PubMed PMID: 22045184]
[14]
Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer causes & control : CCC. 2008 May:19(4):379-90
[PubMed PMID: 18064533]
[15]
Wu SJ,Huang SY,Lin CT,Lin YJ,Chang CJ,Tien HF, The incidence of chronic lymphocytic leukemia in Taiwan, 1986-2005: a distinct increasing trend with birth-cohort effect. Blood. 2010 Nov 25
[PubMed PMID: 20713960]
[16]
Miranda-Filho A, Piñeros M, Ferlay J, Soerjomataram I, Monnereau A, Bray F. Epidemiological patterns of leukaemia in 184 countries: a population-based study. The Lancet. Haematology. 2018 Jan:5(1):e14-e24. doi: 10.1016/S2352-3026(17)30232-6. Epub
[PubMed PMID: 29304322]
Level 2 (mid-level) evidence
[17]
Fleming AF. The epidemiology of lymphomas and leukaemias in Africa--an overview. Leukemia research. 1985:9(6):735-40
[PubMed PMID: 2989624]
Level 3 (low-level) evidence
[18]
Oloo AJ, Ogada TA. Chronic lymphocytic leukaemia (CLL): clinical study at Kenyatta National Hospital (KNH). East African medical journal. 1984 Nov:61(11):797-801
[PubMed PMID: 6535701]
[19]
Little MP,Wakeford R,Borrego D,French B,Zablotska LB,Adams MJ,Allodji R,de Vathaire F,Lee C,Brenner AV,Miller JS,Campbell D,Pearce MS,Doody MM,Holmberg E,Lundell M,Sadetzki S,Linet MS,Berrington de González A, Leukaemia and myeloid malignancy among people exposed to low doses (<100 mSv) of ionising radiation during childhood: a pooled analysis of nine historical cohort studies. The Lancet. Haematology. 2018 Aug;
[PubMed PMID: 30026010]
[20]
Casola S, Perucho L, Tripodo C, Sindaco P, Ponzoni M, Facchetti F. The B-cell receptor in control of tumor B-cell fitness: Biology and clinical relevance. Immunological reviews. 2019 Mar:288(1):198-213. doi: 10.1111/imr.12738. Epub
[PubMed PMID: 30874349]
[21]
PDQ Adult Treatment Editorial Board. Chronic Lymphocytic Leukemia Treatment (PDQ®): Health Professional Version. PDQ Cancer Information Summaries. 2002:():
[PubMed PMID: 26389470]
[22]
Patrussi L, Capitani N, Baldari CT. Abnormalities in chemokine receptor recycling in chronic lymphocytic leukemia. Cellular and molecular life sciences : CMLS. 2019 Aug:76(16):3249-3261. doi: 10.1007/s00018-019-03058-9. Epub 2019 Mar 4
[PubMed PMID: 30830241]
[23]
Ghia P,Caligaris-Cappio F, Monoclonal B-cell lymphocytosis: right track or red herring? Blood. 2012 May 10
[PubMed PMID: 22422819]
[24]
Dühren-von Minden M, Übelhart R, Schneider D, Wossning T, Bach MP, Buchner M, Hofmann D, Surova E, Follo M, Köhler F, Wardemann H, Zirlik K, Veelken H, Jumaa H. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012 Sep 13:489(7415):309-12. doi: 10.1038/nature11309. Epub
[PubMed PMID: 22885698]
[25]
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21:131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14
[PubMed PMID: 29540348]
[26]
Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975 Aug:46(2):219-34
[PubMed PMID: 1139039]
[27]
Binet JL,Auquier A,Dighiero G,Chastang C,Piguet H,Goasguen J,Vaugier G,Potron G,Colona P,Oberling F,Thomas M,Tchernia G,Jacquillat C,Boivin P,Lesty C,Duault MT,Monconduit M,Belabbes S,Gremy F, A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981 Jul 1
[PubMed PMID: 7237385]
[28]
Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Seminars in oncology. 1998 Feb:25(1):80-97
[PubMed PMID: 9482530]
[29]
Dearden C, Wade R, Else M, Richards S, Milligan D, Hamblin T, Catovsky D, UK National Cancer Research Institute (NCRI), Haematological Oncology Clinical Studies Group, NCRI CLL Working Group. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood. 2008 Feb 15:111(4):1820-6
[PubMed PMID: 18055869]
[30]
Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F, Girelli G. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood. 2000 May 1:95(9):2786-92
[PubMed PMID: 10779422]
[31]
Visco C,Ruggeri M,Laura Evangelista M,Stasi R,Zanotti R,Giaretta I,Ambrosetti A,Madeo D,Pizzolo G,Rodeghiero F, Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood. 2008 Feb 1
[PubMed PMID: 17986663]
[32]
Parikh SA, Leis JF, Chaffee KG, Call TG, Hanson CA, Ding W, Chanan-Khan AA, Bowen D, Conte M, Schwager S, Slager SL, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. Cancer. 2015 Sep 1:121(17):2883-91. doi: 10.1002/cncr.29438. Epub 2015 Apr 30
[PubMed PMID: 25931291]
[33]
Agnew KL, Ruchlemer R, Catovsky D, Matutes E, Bunker CB. Cutaneous findings in chronic lymphocytic leukaemia. The British journal of dermatology. 2004 Jun:150(6):1129-35
[PubMed PMID: 15214899]
[34]
Robak E, Robak T. Skin lesions in chronic lymphocytic leukemia. Leukemia & lymphoma. 2007 May:48(5):855-65
[PubMed PMID: 17487727]
[35]
WEED RI. EXAGGERATED DELAYED HYPERSENSITIVITY TO MOSQUITO BITES IN CHRONIC LYMPHOCYTIC LEUKEMIA. Blood. 1965 Sep:26():257-68
[PubMed PMID: 14332055]
[36]
Grandi V, Maglie R, Antiga E, Vannucchi M, Delfino C, Lastrucci I, Gunnella S, Ciolli S, Quintarelli L, Massi D, Caproni M, Pimpinelli N. Eosinophilic dermatosis of hematologic malignancy: A retrospective cohort of 37 patients from an Italian center. Journal of the American Academy of Dermatology. 2019 Jul:81(1):246-249. doi: 10.1016/j.jaad.2018.11.048. Epub 2018 Dec 5
[PubMed PMID: 30528498]
Level 2 (mid-level) evidence
[37]
Nowakowski GS, Hoyer JD, Shanafelt TD, Geyer SM, LaPlant BR, Call TG, Jelinek DF, Zent CS, Kay NE. Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test. Mayo Clinic proceedings. 2007 Apr:82(4):449-53
[PubMed PMID: 17418074]
Level 2 (mid-level) evidence
[38]
Rawstron AC,Kreuzer KA,Soosapilla A,Spacek M,Stehlikova O,Gambell P,McIver-Brown N,Villamor N,Psarra K,Arroz M,Milani R,de la Serna J,Cedena MT,Jaksic O,Nomdedeu J,Moreno C,Rigolin GM,Cuneo A,Johansen P,Johnsen HE,Rosenquist R,Niemann CU,Kern W,Westerman D,Trneny M,Mulligan S,Doubek M,Pospisilova S,Hillmen P,Oscier D,Hallek M,Ghia P,Montserrat E, Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry. Part B, Clinical cytometry. 2018 Jan
[PubMed PMID: 29024461]
[39]
Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL, Lozanski G, Colomer D, Moreno C, Geuna M, Evans PA, Natkunam Y, Coutre SE, Avery ED, Rassenti LZ, Kipps TJ, Caligaris-Cappio F, Kneba M, Byrd JC, Hallek MJ, Montserrat E, Hillmen P. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007 May:21(5):956-64
[PubMed PMID: 17361231]
[40]
Potter KN, Mockridge CI, Neville L, Wheatley I, Schenk M, Orchard J, Duncombe AS, Packham G, Stevenson FK. Structural and functional features of the B-cell receptor in IgG-positive chronic lymphocytic leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Mar 15:12(6):1672-9
[PubMed PMID: 16551848]
[41]
Geisler CH, Larsen JK, Hansen NE, Hansen MM, Christensen BE, Lund B, Nielsen H, Plesner T, Thorling K, Andersen E. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood. 1991 Oct 1:78(7):1795-802
[PubMed PMID: 1717071]
[42]
Fournier S,Delespesse G,Rubio M,Biron G,Sarfati M, CD23 antigen regulation and signaling in chronic lymphocytic leukemia. The Journal of clinical investigation. 1992 Apr
[PubMed PMID: 1532590]
[43]
Freedman AS, Boyd AW, Bieber FR, Daley J, Rosen K, Horowitz JC, Levy DN, Nadler LM. Normal cellular counterparts of B cell chronic lymphocytic leukemia. Blood. 1987 Aug:70(2):418-27
[PubMed PMID: 3496927]
[44]
Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. The New England journal of medicine. 2000 Dec 28:343(26):1910-6
[PubMed PMID: 11136261]
[45]
Reddy KS. Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridisation panel. British journal of haematology. 2006 Mar:132(6):705-22
[PubMed PMID: 16487171]
[46]
Knuutila S, Elonen E, Teerenhovi L, Rossi L, Leskinen R, Bloomfield CD, de la Chapelle A. Trisomy 12 in B cells of patients with B-cell chronic lymphocytic leukemia. The New England journal of medicine. 1986 Apr 3:314(14):865-9
[PubMed PMID: 3081810]
[47]
Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer research. 1991 Dec 1:51(23 Pt 1):6304-11
[PubMed PMID: 1933891]
[48]
Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proceedings of the National Academy of Sciences of the United States of America. 1992 Aug 15:89(16):7491-5
[PubMed PMID: 1323840]
[49]
Khanna KK, Keating KE, Kozlov S, Scott S, Gatei M, Hobson K, Taya Y, Gabrielli B, Chan D, Lees-Miller SP, Lavin MF. ATM associates with and phosphorylates p53: mapping the region of interaction. Nature genetics. 1998 Dec:20(4):398-400
[PubMed PMID: 9843217]
[50]
Ambrose M, Gatti RA. Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. Blood. 2013 May 16:121(20):4036-45. doi: 10.1182/blood-2012-09-456897. Epub 2013 Feb 25
[PubMed PMID: 23440242]
[51]
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 19:127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15
[PubMed PMID: 26980727]
[52]
Lipshutz MD, Mir R, Rai KR, Sawitsky A. Bone marrow biopsy and clinical staging in chronic lymphocytic leukemia. Cancer. 1980 Sep 15:46(6):1422-7
[PubMed PMID: 7417943]
[53]
Pangalis GA, Boussiotis VA, Kittas C. B-chronic lymphocytic leukemia. Disease progression in 150 untreated stage A and B patients as predicted by bone marrow pattern. Nouvelle revue francaise d'hematologie. 1988:30(5-6):373-5
[PubMed PMID: 3222147]
[54]
Rozman C, Montserrat E, Rodríguez-Fernández JM, Ayats R, Vallespí T, Parody R, Ríos A, Prados D, Morey M, Gomis F. Bone marrow histologic pattern--the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood. 1984 Sep:64(3):642-8
[PubMed PMID: 6466871]
Level 3 (low-level) evidence
[55]
Borthakur G, O'Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, Kantarjian HM, Lerner S, Keating MJ. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors. British journal of haematology. 2007 Mar:136(6):800-5
[PubMed PMID: 17341265]
[56]
. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. The French Cooperative Group on Chronic Lymphocytic Leukemia. Blood. 1990 Apr 1:75(7):1414-21
[PubMed PMID: 2180492]
Level 1 (high-level) evidence
[57]
. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. Journal of the National Cancer Institute. 1999 May 19:91(10):861-8
[PubMed PMID: 10340906]
Level 1 (high-level) evidence
[58]
Hoechstetter MA, Busch R, Eichhorst B, Bühler A, Winkler D, Eckart MJ, Vehling-Kaiser U, Schimke H, Jäger U, Hurtz HJ, Hopfinger G, Hartmann F, Fuss H, Abenhardt W, Blau I, Freier W, Müller L, Goebeler M, Wendtner CM, Bahlo J, Fischer K, Bentz M, Emmerich B, Döhner H, Hallek M, Stilgenbauer S. Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia. 2017 Dec:31(12):2833-2837. doi: 10.1038/leu.2017.246. Epub 2017 Aug 14
[PubMed PMID: 28804126]
[59]
Condoluci A,Terzi di Bergamo L,Langerbeins P,Hoechstetter MA,Herling CD,De Paoli L,Delgado J,Rabe KG,Gentile M,Doubek M,Mauro FR,Chiodin G,Mattsson M,Bahlo J,Cutrona G,Kotaskova J,Deambrogi C,Smedby KE,Spina V,Bruscaggin A,Wu W,Moia R,Bianchi E,Gerber B,Zucca E,Gillessen S,Ghielmini M,Cavalli F,Stussi G,Hess MA,Baumann TS,Neri A,Ferrarini M,Rosenquist R,Forconi F,Foà R,Pospisilova S,Morabito F,Stilgenbauer S,Döhner H,Parikh SA,Wierda WG,Montserrat E,Gaidano G,Hallek M,Rossi D, International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020 May 21
[PubMed PMID: 32267500]
[60]
Morrison WH, Hoppe RT, Weiss LM, Picozzi VJ Jr, Horning SJ. Small lymphocytic lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1989 May:7(5):598-606
[PubMed PMID: 2651577]
[61]
Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. The New England journal of medicine. 2014 Mar 20:370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8
[PubMed PMID: 24401022]
[62]
Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. The New England journal of medicine. 2019 Aug 1:381(5):432-443. doi: 10.1056/NEJMoa1817073. Epub
[PubMed PMID: 31365801]
[63]
Tausch E,Schneider C,Robrecht S,Zhang C,Dolnik A,Bloehdorn J,Bahlo J,Al-Sawaf O,Ritgen M,Fink AM,Eichhorst B,Kreuzer KA,Tandon M,Humphrey K,Jiang Y,Schary W,Bullinger L,Mertens D,Lurà MP,Kneba M,Döhner H,Fischer K,Hallek M,Stilgenbauer S, Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood. 2020 Jun 25
[PubMed PMID: 32206772]
[64]
Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. The New England journal of medicine. 2019 Jun 6:380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4
[PubMed PMID: 31166681]
[65]
Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. The New England journal of medicine. 2018 Dec 27:379(26):2517-2528. doi: 10.1056/NEJMoa1812836. Epub 2018 Dec 1
[PubMed PMID: 30501481]
[66]
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O, Novak J, Ben-Yehuda D, Strugov V, Gill D, Gribben JG, Hsu E, Lih CJ, Zhou C, Clow F, James DF, Styles L, Flinn IW. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. The Lancet. Oncology. 2019 Jan:20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3
[PubMed PMID: 30522969]
Level 1 (high-level) evidence
[67]
Burger JA,Barr PM,Robak T,Owen C,Ghia P,Tedeschi A,Bairey O,Hillmen P,Coutre SE,Devereux S,Grosicki S,McCarthy H,Simpson D,Offner F,Moreno C,Dai S,Lal I,Dean JP,Kipps TJ, Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020 Mar
[PubMed PMID: 31628428]
[68]
Polizzotto MN, Tam CS, Milner A, Januszewicz EH, Prince HM, Westerman D, Wolf MM, Seymour JF. The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders. Cancer. 2006 Aug 15:107(4):773-80
[PubMed PMID: 16847886]
[69]
Molica S, Shanafelt TD, Giannarelli D, Gentile M, Mirabelli R, Cutrona G, Levato L, Di Renzo N, Di Raimondo F, Musolino C, Angrilli F, Famà A, Recchia AG, Chaffee KG, Neri A, Kay NE, Ferrarini M, Morabito F. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. American journal of hematology. 2016 Nov:91(11):1090-1095. doi: 10.1002/ajh.24493. Epub 2016 Aug 8
[PubMed PMID: 27465919]
Level 1 (high-level) evidence
[70]
Iskierka-Jażdżewska E, Robak T. Minimizing and managing treatment-associated complications in patients with chronic lymphocytic leukemia. Expert review of hematology. 2020 Jan:13(1):39-53. doi: 10.1080/17474086.2020.1696185. Epub 2019 Nov 30
[PubMed PMID: 31747803]
[71]
O'Brien SM,Byrd JC,Hillmen P,Coutre S,Brown JR,Barr PM,Barrientos JC,Devereux S,Robak T,Reddy NM,Kipps TJ,Tedeschi A,Cymbalista F,Ghia P,Chang S,Ninomoto J,James DF,Burger JA, Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. American journal of hematology. 2019 May
[PubMed PMID: 30767298]
[72]
Gohil SH, Wu CJ. Dissecting CLL through high-dimensional single-cell technologies. Blood. 2019 Mar 28:133(13):1446-1456. doi: 10.1182/blood-2018-09-835389. Epub 2019 Feb 6
[PubMed PMID: 30728142]